Dabigatran etexilate (Pradaxa) is a type of oral anticoagulant medicine which is used in the prevention of blood clots and prevention of stroke. It is supplied by Boehringer Ingelheim Ltd
It is used to prevent blood clots forming in people who have had surgery involving a knee or hip replacement and, to help prevent strokes in people who are considered to be at risk of a stroke following a diagnosis of Atrial Fibrillation, a condition that causes an irregular and often abnormally fast heart rate which disturbs the heart rhythm.
In 2008, The National Institute for Health and Care Excellence (NICE) and Scottish Medicines Consortium (SMC) recommended Dabigatran etexilate as an option for the primary prevention of venous thromboembolic events in adults who have undergone total hip or knee replacement surgery.
In 2011 and 2012 respectively, NICE and SMC recommended Dabigatran etexilate as an option for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
In 2014, NICE and SMC recommended Dabigatran etexilate as an option for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism